Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study. Rheumatology and therapy Genovese, M. C., Greenwald, M. W., Gutierrez-Urena, S. R., Cardiel, M. H., Poiley, J. E., Zubrzycka-Sienkiewicz, A., Codding, C. E., Wang, A., He, W., Amos, R., Vinueza, R., Wang, X., Garg, J. P., Kivitz, A. J. 2019

Abstract

INTRODUCTION: Peficitinib is a novel orally bioavailable, once-daily Janus kinase (JAK) inhibitor approved in Japan for the treatment of rheumatoid arthritis (RA). This 2-year extension study of two global phaseIIbtrials investigated the long-term safety and effectiveness of peficitinib.METHODS: All eligible patients with moderate-to-severe RA including patients in the placebo group who participated in one of two global phase IIb trials ('with methotrexate' or 'without methotrexate') were included in this 2-year open-label extension study and were converted to peficitinib100mg once daily. The primary objective was to evaluate an additional 2years of safety by assessing treatment-emergent adverse events (AEs) and clinical laboratory evaluations for 105weeks. Evaluation of an additional 2years of effectiveness using American College of Rheumatology (ACR) 20/50/70 responses was the exploratory objective.RESULTS: Overall, 611 patients were enrolled in the extension study: 319 (52.2%) patients completed the study and 292 (48%) discontinued treatment, including for withdrawal of patient consent (n=96), failure to achieve low disease activity (n=62), and AE not including death (n=41). AEs were reported in 463(76%) patients. The most common AEs (per 100 patient-years) were upper respiratory tract infections (9.9) and urinary tract infections (7.2). Serious AEs were reported in 80 (13%) patients, with incidences per 100 patient-years of serious infections 2.7, herpes zoster 1.5 (including one herpes zoster ophthalmic), and malignancies 0.6 (most frequently basal cell carcinoma). At week 105, 269 (44%) patients demonstrated an ACR20 response relative to their respective phaseIIb trial baselines.CONCLUSION: Among 319 patients who completed this 2-year extension of two global phase IIb studies, peficitinib 100mg once daily demonstrated a stable safety profile and sustained effectiveness in patients with moderate-to-severe RA.TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT01711814. Registered 19 October 2012.FUNDING: Astellas Pharma Global Development, Inc.

View details for DOI 10.1007/s40744-019-00167-6

View details for PubMedID 31410787